OR26-02 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED), Binds To A Distinct Epitope From Teprotumumab

Disclosure: V. Bedian: Employee; Self; Viridian Therapeutics Inc. J.C. Tsai: Employee; Self; Viridian Therapeutics Inc. R.N. Newell: Employee; Self; Viridian Therapeutics Inc. Y. Zhao: Employee; Self; Viridian Therapeutics Inc. Introduction: VRDN-001, a full antagonist antibody to IGF-1 receptor (IG...

Descripción completa

Detalles Bibliográficos
Autores principales: Bedian, Vahe, Tsai, Jordan C, Newell, Rachel N, Zhao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554507/
http://dx.doi.org/10.1210/jendso/bvad114.2051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554507/
http://dx.doi.org/10.1210/jendso/bvad114.2051

Ejemplares similares